Total Payments
$207,527
2024 Payments
$14,939
Companies
18
Transactions
307
Medicare Patients
312
Medicare Billing
$36,427
Payment Breakdown by Category
Other$170,523 (82.2%)
Travel$18,100 (8.7%)
Consulting$11,310 (5.4%)
Food & Beverage$6,065 (2.9%)
Research$1,529 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $166,200 | 66 | 80.1% |
| Travel and Lodging | $18,100 | 68 | 8.7% |
| Consulting Fee | $11,310 | 3 | 5.4% |
| Food and Beverage | $6,065 | 165 | 2.9% |
| Honoraria | $4,056 | 2 | 2.0% |
| Unspecified | $1,529 | 2 | 0.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $267.10 | 1 | 0.1% |
Payments by Type
General
$205,998
305 transactions
Research
$1,529
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $164,829 | 233 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $27,575 | 27 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $7,404 | 8 | $0 (2018) |
| Intercept Pharmaceuticals, Inc. | $5,048 | 12 | $0 (2020) |
| Covidien LP | $1,451 | 1 | $0 (2019) |
| Echosens North America, Inc. | $537.61 | 1 | $0 (2018) |
| FUJIFILM Medical Systems USA, Inc. | $267.10 | 1 | $0 (2018) |
| Romark Laboratories, LC | $153.79 | 10 | $0 (2020) |
| AbbVie, Inc. | $62.09 | 3 | $0 (2018) |
| Madrigal Pharmaceuticals | $46.29 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,939 | 14 | Gilead Sciences, Inc. ($14,871) |
| 2023 | $23,603 | 28 | Gilead Sciences, Inc. ($23,603) |
| 2022 | $30,193 | 31 | Gilead Sciences, Inc. ($30,193) |
| 2021 | $16,131 | 22 | Gilead Sciences, Inc. ($16,115) |
| 2020 | $17,078 | 47 | Gilead Sciences, Inc. ($15,088) |
| 2019 | $24,783 | 45 | Gilead Sciences, Inc. ($20,136) |
| 2018 | $32,522 | 56 | Gilead Sciences, Inc. ($24,182) |
| 2017 | $48,280 | 64 | Merck Sharp & Dohme Corporation ($27,561) |
All Payment Transactions
307 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $75.83 | General |
| 11/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $2.48 | General |
| 11/17/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $46.29 | General |
| Category: LIVER DISEASE | ||||||
| 11/16/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $144.84 | General |
| Category: INFLAM | ||||||
| 10/07/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,930.00 | General |
| Category: INFLAM | ||||||
| 10/04/2024 | Gilead Sciences, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,930.00 | General |
| 10/02/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $124.74 | General |
| Category: INFLAM | ||||||
| 10/02/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.89 | General |
| 09/25/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $800.00 | General |
| Category: INFLAM | ||||||
| 09/05/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,790.00 | General |
| Category: HCV | ||||||
| 09/04/2024 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $30.97 | General |
| Category: HCV | ||||||
| 09/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $1.44 | General |
| 05/22/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: Immunology | ||||||
| 01/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.76 | General |
| 12/06/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $15.47 | General |
| Category: HCV | ||||||
| 11/13/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,550.00 | General |
| Category: HCV | ||||||
| 11/09/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $99.33 | General |
| Category: HCV | ||||||
| 10/19/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $6.55 | General |
| Category: HCV | ||||||
| 10/13/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,550.00 | General |
| Category: HCV | ||||||
| 10/11/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $24.48 | General |
| Category: HCV | ||||||
| 10/09/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $2.30 | General |
| 08/21/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $23.58 | General |
| Category: HCV | ||||||
| 08/08/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,550.00 | General |
| Category: HCV | ||||||
| 07/25/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,620.00 | General |
| Category: HCV | ||||||
| 07/25/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Travel and Lodging | In-kind items and services | $107.42 | General |
| Category: HCV | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| THE BLINK COVSBCC0549 STUDY | Covidien LP | $1,451 | 1 |
| STELLAR-3 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis | Gilead Sciences, Inc. | $77.86 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 205 | 207 | $157,558 | $25,759 |
| 2022 | 1 | 19 | 19 | $15,808 | $2,402 |
| 2020 | 3 | 88 | 108 | $33,986 | $8,265 |
Total Patients
312
Total Services
334
Medicare Billing
$36,427
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 47 | 48 | $47,328 | $9,205 | 19.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 56 | 57 | $47,424 | $6,420 | 13.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 23 | 23 | $15,939 | $3,686 | 23.1% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 29 | 29 | $17,545 | $2,729 | 15.6% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 13 | 13 | $9,009 | $2,180 | 24.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 37 | 37 | $20,313 | $1,540 | 7.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 19 | 19 | $15,808 | $2,402 | 15.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 62 | 80 | $20,320 | $5,992 | 29.5% |
| 45380 | Biopsy of large bowel using an endoscope | Facility | 2020 | 11 | 11 | $10,725 | $1,560 | 14.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 15 | 17 | $2,941 | $712.71 | 24.2% |
About Dr. David Pound, M.D
Dr. David Pound, M.D is a Gastroenterology healthcare provider based in Indianapolis, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1760488563.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Pound, M.D has received a total of $207,527 in payments from pharmaceutical and medical device companies, with $14,939 received in 2024. These payments were reported across 307 transactions from 18 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($166,200).
As a Medicare-enrolled provider, Pound has provided services to 312 Medicare beneficiaries, totaling 334 services with total Medicare billing of $36,427. Data is available for 3 years (2020–2023), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Indianapolis, IN
- Active Since 06/27/2005
- Last Updated 03/09/2020
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1760488563
Products in Payments
- Epclusa (Drug) $132,941
- ZEPATIER (Drug) $27,567
- Livdelzi (Drug) $6,000
- Vosevi (Drug) $4,362
- Harvoni (Drug) $2,567
- Fibroscan (Device) $537.61
- ESD - Core Endoscopy (Device) $267.10
- ALINIA (Drug) $86.05
- Entyvio (Biological) $57.43
- RESMETIROM (Drug) $46.29
- Alinia Tablets 500mg 30 count bottle (Drug) $46.16
- Creon (Drug) $38.67
- OCA (Drug) $24.95
- Mavyret (Drug) $23.42
- STELARA (Biological) $21.89
- Alinia (Drug) $21.58
- Cimzia (Drug) $16.28
- XIFAXAN (Drug) $16.07
- XELJANZ (Drug) $15.53
- PREPOPIK (Drug) $13.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Indianapolis
Douglas Rex, M.d, M.D
Gastroenterology — Payments: $785,487
Gastroenterology $785,487
Ajay Jain, Md, MD
Gastroenterology — Payments: $435,795
Gastroenterology $435,795
Raj Vuppalanchi, M.d, M.D
Gastroenterology — Payments: $183,853
Gastroenterology $183,853
Thomas Imperiale, M.d, M.D
Gastroenterology — Payments: $154,570
Gastroenterology $154,570
Glen Lehman, M.d, M.D
Gastroenterology — Payments: $98,291
Gastroenterology $98,291
Dr. Michael Elmore, M.d, M.D
Gastroenterology — Payments: $95,868
Gastroenterology $95,868